Afutuzumab is primarily utilized in the field of oncology, particularly in the treatment of certain types of cancers. It is an antibody designed to target specific antigens present on the surface of cancer cells, making it a valuable tool in targeted cancer therapies. By binding to these antigens, afutuzumab can help to inhibit the growth and proliferation of malignant cells, potentially leading to reduced tumor size and improved patient outcomes. Additionally, it may be used in combination with other therapeutic agents to enhance the overall efficacy of cancer treatment regimens. Its application is often explored in clinical trials to assess its effectiveness and safety in various cancer types, contributing to the advancement of personalized medicine in oncology.